Literature DB >> 33135738

Trimethylamine N-Oxide is Associated with Heart Failure Risk in Patients with Preserved Ejection Fraction.

Zengxiang Dong1,2, Sijia Zheng1, Zhaoqian Shen2, Yingchun Luo2, Xin Hai1.   

Abstract

BACKGROUND: Trimethylamine N-oxide (TMAO) has been considered to be an independent risk factor of heart failure (HF).
OBJECTIVES: To further determine the plasma levels of TMAO in patients who have HF with preserved ejection fraction (HFpEF), and to analyze the relationship between TMAO and HFpEF risk.
METHODS: A total of 57 control participants and 61 patients with HFpEF were recruited. We measured and analyzed plasma levels of TMAO and performed biochemical examination of all patients.
RESULTS: The mean (SD) plasma levels of TMAO in patients with HFpEF (6.84 [1.12] μmol/L) were significantly higher than in controls (1.63 [0.08] μmol/L; P <.01). The area under the curve (AUC) of TMAO and N-terminal pro b-type natriuretic peptide (NT-proBNP) was 0.817 and 0.924, respectively, which were determined by receiver operating characteristic (ROC) analysis. TMAO was an independent risk factor in patients with HFpEF, as revealed by univariate and multivariate logistic regression analysis. The level of TMAO was correlated with blood urea nitrogen (BUN), creatinine, and NT-proBNP.
CONCLUSIONS: TMAO level was highly associated with HFpEF risk. © American Society for Clinical Pathology 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  N-terminal pro b-type natriuretic peptide; gut microbiota; heart failure; preserved ejection fraction; risk factors; trimethylamine N-oxide

Mesh:

Substances:

Year:  2021        PMID: 33135738     DOI: 10.1093/labmed/lmaa075

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  1 in total

Review 1.  The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure.

Authors:  Kelley M Anderson; Erin P Ferranti; Emily Couvillon Alagha; Emma Mykityshyn; Casey E French; Carolyn Miller Reilly
Journal:  Heart Fail Rev       Date:  2022-06-21       Impact factor: 4.654

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.